



# Revealing Structural Variation that Matters with Optical Genome Mapping

bionano™

---

10.24.2022

# Modern Cytogenetics Laboratories are Facing Analytical and Operational Challenges

## Market Drivers & Pressures



### Strong demand for analysis of chromosomal aberrations

Multiple medical guidelines drive need for more comprehensive cytogenetic testing across applications



### Increasing test volume

Global demand for cytogenetic services is expected to grow by over 8% per year



### Growing test complexity

Discoveries in genomics and evolving guidelines have resulted in an increasing number of biomarkers and reflex pathways

## Challenges Labs Face



### Complex Workflows

Traditional cytogenetic technologies like karyotyping and FISH have complex prep and manual analysis steps, limiting overall throughput



### Resource constraints

The number of trained clinical cytogeneticists is expected to decline — creating challenges for meeting growing test demand



### Technology limitations

Current cytogenetic technologies may be limited in their ability to meet the needs of growing test menus and complex biomarkers

# Current Approaches to Assess Genomic Aberrations Fall Short



Traditional Techniques  
Fail to Realize  
the Promise of  
Precision Medicine



50%\*

of samples analyzed fail to yield  
meaningful results

\*References: 1. Tsui et al. Blood Cancer J. 2020. PMID 33077814. 2. Nimer. Best Pract Res Clin Haematol. 2008. PMID: 18342811. 3. Walker et al. Expert Rev Hematol. 2012. PMID: 23146058. 4. Graessner et al. Eur J Hum Genet. 2021. PMID: 34140650. 5. Seo et al. Mol Med. 2022. PMID: 35346031.

“ I do sign our chromosomal analysis by Karyotype on a regular basis, in diseases like AML or heme malignancies. In around maybe 40-50% of these cases, they come back with a normal Karyotype, or the FISH result is negative.”

Dr. Ravindra Kolhe, MD, PhD, FCAP  
Professor, Dept of Pathology  
Augusta University



# OGM Solves for the Limitations of Current Methods for Chromosomal Aberration Detection

Method	Karyotyping	FISH	CMA	OGM
Resolution	>5-10 Mbp	>100-200 kbp	>50-100 kbp	>500 bp
Detection bias	Hypothesis-free	Single probe	Design bias	Hypothesis-free
Detection of balanced rearrangements	Yes	Yes	No	Yes
Cell culture needed	Yes	No	No	No
Average TAT	1-2 weeks	3-5 days	<1 week	< 1 week
Digital analysis	No	No	Yes	Yes
Sample-to-answer platform	No	No	Yes	Yes

Broeckel U et al. Multisite Study of Optical Genome Mapping of Retrospective and Prospective Constitutional Disorder Cohorts. medRxiv 2022.12.26.22283900; doi: <https://doi.org/10.1101/2022.12.26.22283900>; Stevenson RE et al. Multisite evaluation and validation of Optical Genome Mapping for prenatal genetic testing. medRxiv 2022.12.19.22283552; doi: <https://doi.org/10.1101/2022.12.19.22283552>; Pang A et al. Clinical Validation of Optical Genome Mapping for the Detection of Structural Variations in Hematological Malignancies. medRxiv 2022.12.27.22283973; doi: <https://doi.org/10.1101/2022.12.27.22283973>

# OGM Provides Improvements as Compared to Classical Cytogenetics

Variant Type	Karyotype	FISH	CMA	OGM
Aneuploidy	✓	✓ Targeted	✓	✓
Deletion	✓ >5–10Mbp	✓ Targeted	✓	✓
Duplication	✓ >5–10Mbp	✓ Targeted	✓	✓
Translocation	✓ >5–10Mbp	✓ Targeted	✗	✓
Inversion	✓ >5–10Mbp	✓ Targeted	✗	✓
AOH	✗	✗	✓	✓ Germline
Repeat Expansion	✗	✗	✗	✓ Limited to large repeats
Repeat Contraction	✗	✗	✗	✓
SNV	✗	✗	✗	✗

“Optical genome mapping has uncovered previously hidden structural variation that has been inaccessible largely because of the limitations and low resolution of the standard technologies that we relied upon in the past.”

Brynn Levy  
Professor, Department of Pathology & Cell Biology  
at College of Physicians and Surgeons  
Columbia University

**bionano**<sup>™</sup>



“30% of previously unsolved cases for B-ALL, which previously underwent karyotype + FISH + microarray + NGS, were solved using OGM.”

*Dr. Gordana Raca  
Children's Hospital Los Angeles  
California, USA*





“With OGM we are changing subjectivity to objectivity in going from a visual microscope-based karyotype to a high-resolution digital output.”

*Dr. Adam C. Smith  
UHN Toronto  
Toronto, Canada*



# Multisite Validation Study with OGM in Hematological Malignancies

OGM results highly concordant with SOC + OGM led to MORE REPORTABLE VARIANTS

207	<b>Datasets evaluated</b> (including replicated), from: <ul style="list-style-type: none"><li>• 68 Hematological malignancies samples</li><li>• 27 controls</li><li>• 2 cancer cell lines</li></ul>
100%	100% Concordance with SOC 100% Sensitivity 100% Specificity 100% Accuracy 100% Precision 100% PPV 100% NPV
96%	Reproducibility
37%	Cases for which OGM was able to find additional significant variants
5% to 10%	<b>Limit of Detection:</b> ~ 5% for Structural Variants ~ 10% for CNVs At 1.5Tbp (≥300x post-analytical effective coverage)

Different Sites Involved:



“

The results of this validation study demonstrate OGM's superiority over traditional SOC methods for the detection of SVs for the accurate analysis of various hematological malignancies.

OGM ability to detect SVs at high resolution and high sensitivity holds promise for OGM to be a first tier cytogenomic assay for heme cancers.

SOC: standard-of-care

Pang A et al. Clinical Validation of Optical Genome Mapping for the Detection of Structural Variations in Hematological Malignancies.

medRxiv 2022.12.27.22283973; doi: <https://doi.org/10.1101/2022.12.27.22283973>

# Multisite Validation Study with OGM in Hematological Malignancies

OGM results highly concordant with SOC + OGM led to MORE REPORTABLE VARIANTS

## OGM Performance compared to SOC



### High analytical concordance

100% concordance with SOC



### Better characterization and resolution of SVs and CNVs


highest resolution and sensitivity attainable till date



### Revealed novel, pathogenic SVs not reported by SOC

37% of the cases contained **novel** clinically significant SVs not reported by SOC

## OGM workflow allows consolidation and simplification, leading to cost and time savings for the lab



Combination of karyotyping, multiple FISH probes, and arrays are typically used to obtain information. **Many aberrations are cryptic to these methods.** OGM helps **consolidate** and **simplify** workflow, while also **maximizing findings**.

# Multisite Prospective and Retrospective Study with OGM in Postnatal

OGM results highly concordant with SOC + OGM led to MORE REPORTABLE VARIANTS

>1,000	Datapoints collected in this large study, and compared to SOC (Karyotyping, FISH, microarray, Southern Blotting and PCR)
99.6%	Full or partial concordance achieved between OGM and SOC results (98.7% fully concordant)
10.1% to 14.8%	Incremental variants reported, when OGM was combined with SOC (10.1% gain in prospective cases; 14.8% in Autism Spectrum Disorder cases)

Many US sites involved in study:



The increase in reportable yield by OGM was directly attributable to **genomic aberrations that were not discovered using SOC methods.**

SOC: standard-of-care  
Broeckel U et al. Multisite Study of Optical Genome Mapping of Retrospective and Prospective Constitutional Disorder Cohorts.  
medRxiv 2022.12.26.22283900; doi: <https://doi.org/10.1101/2022.12.26.22283900>

# Modern Cytogenomic Analysis. Lower Operational Burden.

## Reveal more variation that matters



Create an objective, high-resolution digital karyotype

1000x resolution with automated data analysis and interpretation tools



>99% concordance with traditional techniques


Multiple studies demonstrate OGM's ability to accurately and reliably identify chromosomal aberrations found by karyotyping, FISH and CMA



Reveal more genetic variation that matters

Analyze all guideline-recommended biomarkers and drive discovery with identification of novel findings undetected by traditional techniques

## Simplify and scale your laboratory operations



Streamline your workflow

Single, alternative workflow to karyotyping, CMA and FISH that can simplify comprehensive chromosomal analysis



Lower your resource burden

Onboard new staff members faster, reduce the need for cell culture, and lower your hands-on time overall



Sample to answer in <1 week


Eliminate complex reflex workflows and find the answers you want in less time

# Next Steps



## Consultative Discussion

Dive deeper on OGM with a Technical Specialist specific to the needs in your lab.




## Data Services Project

See what OGM can do with your samples in our lab.

# Multiple Institutions Have Benefited from OGM



# Numerous Publications on Oncology and Constitutional Space



Sample of some key publications, not representative of entire reference library.



# Growing number of Bionano OGM publications

**ARTICLE OPEN**  
MELODYSPASTIC NEOPLASIA

**High-resolution structural variant profiling of myeloid syndromes by optical genome mapping uncovers aberrations of prognostic and therapeutic significance**

Hui Yang<sup>1</sup>, Guillermo Garcia-Monero<sup>1</sup>, Koji Sasaki<sup>1</sup>, Guillermo Morizabán-Bravo<sup>1</sup>, Zhenya Tang<sup>2</sup>, Yue Wu<sup>3</sup>, Kelly Chen<sup>4</sup>, Diana Ruiz<sup>1</sup>, Ha Nguyen<sup>1</sup>, Anandh Kalia<sup>1</sup>, Manjivath Nimmakayala<sup>1</sup>, Carlos Buzo-Ramos<sup>1</sup>, L. Jeffrey Medeiros<sup>1</sup>, Rajyalakshmi Luthra<sup>1</sup> and Rashmi Kanagal-Shamanna<sup>1</sup>\*

**Multi-site Technical Performance and Concordance of Constitutional Postnatal Study for SV, CNV, and Aneuploidy**

M. Anwar Iqbal<sup>1\*</sup>, Ulrich Broecker<sup>2\*</sup>, Brynna Rodriguez<sup>3</sup>, Aaron Stence<sup>4</sup>, Kamel Awayda<sup>5</sup>, G. Aaron Bossler<sup>6</sup>, Peter L. Nagy<sup>6\*</sup>, and Ravindra

**Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping**

Katrina Rack<sup>1</sup> | Jolien De Bie<sup>1,2</sup> | Geneviève Aমেয়ে<sup>1</sup> | Olga Gielen<sup>2,3</sup> | Sofie Demeyer<sup>2,3</sup> | Jan Cooks<sup>2,3,4</sup> | Kim De Keersmaecker<sup>4,5</sup> | Joris R. Vermeulen<sup>6</sup> | Barbara Dewaele<sup>6</sup>

**scientific reports**

**Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities**

Eva Kringsová<sup>1</sup>, Regina Filáreová<sup>1</sup>, Jiří Mlýnská<sup>1</sup>, Jakub Šavara<sup>1</sup>, Jitka Maršuková<sup>1</sup>, Anna Petrášková<sup>2</sup>, Martin Džbán<sup>3</sup>, Jana Balachová<sup>4</sup>, Petra Křiváňská<sup>5</sup>, Tomáš Pátek<sup>6</sup>, Petr Gajdoš<sup>7</sup>, Marek Behulka<sup>8</sup>, Michal Vrána<sup>8</sup> & Tomas Papoušek<sup>1</sup>

**Optical genome mapping enables constitutional chromosomal aberration detection**


Tuomo Mantere,<sup>1,2,3,12</sup> Kornelia Neveling,<sup>1,6,12</sup> Céline Pebrel-Richard,<sup>3</sup> Marion Benoist,<sup>6</sup> Guillaume van der Zande,<sup>1</sup> Ellen Kater-Baats,<sup>3</sup> Imane Baatout,<sup>6</sup> Ronald van Beek,<sup>1</sup> Tony Yammine,<sup>7,8</sup> Michiel Oorsprong,<sup>1</sup> Faten Hsoumi,<sup>6</sup> Daniel Olde-Weghuis,<sup>1</sup> Wed Majdali,<sup>6</sup> Susan Vermeulen,<sup>1</sup> Marc Pauper,<sup>1</sup> Aziza Lelbar,<sup>6</sup> Marian Stevens-Kroef,<sup>1</sup> Damien Sanlaville,<sup>7,9</sup> Jean Michel Dupont,<sup>6,10</sup> Dominique Smeets,<sup>1</sup> Alexander Hoischen,<sup>1,2,11,12\*</sup> Caroline Schluth-Bolard,<sup>7,9,12</sup> and Laila El Khattabi<sup>6,10,12,\*</sup>

**CANCER GENETICS AND EPIGENETICS**

**Optical genome mapping reveals additional information compared to conventional cytogenetics in AML/MDS patients**

Wanda M. Gerding<sup>1</sup> | Marco Tembrink<sup>2</sup> | Verena Nill <sup>3</sup> Thomas Mikal<sup>4</sup> | Fotios Dimitropoulos<sup>5</sup> | Svetlana Ladiges <sup>6</sup> Matthias Eckhardt<sup>2</sup> | Michael Poh<sup>2</sup> | Max Wittenberg<sup>7</sup> Peter Reimer<sup>2</sup> | Roland Schroers<sup>2</sup> | Huu Phuc Nguyen<sup>8</sup>

## Bionano OGM Publications



Sample of some key publications, not representative of entire reference library.

# How We Reveal Structural Variants: Optical Genome Mapping on the Bionano Saphyr<sup>®</sup> System

bionano™



# A End-to-End Solution for Optical Genome Mapping

Sample-to-Answer in as few as 4 days with Sample Preparation, Data Generation, and Analysis

**Sample Preparation**  
(SP and DLS reagent kits)




**2 – 3 days**

**OGM Data Generation**  
(the Saphyr® System)




**1 - 2 days**

**Data analysis  
and Interpretation**  
(Access and Solve software)  
(VIA – coming soon!)




**1 - 2 days**

# Overview of the Saphyr OGM Workflow



## High-throughput, High-resolution Imaging of Megabase Length Molecules



## Sample Types (fresh or frozen)



Blood (650  $\mu$ l)



Bone marrow aspirate



Cultured cells



Tissue





Tumor (5mg)





Cultured amniocytes or CVS samples (1M)


# OGM with Saphyr Uses Nanochannel Arrays to Linearize Ultra-High Molecular Weight DNA



# Optical Genome Mapping as High-Resolution Digital Karyotyping




OGM provides  
~1,000x times more “bands”  
in the form of labels and can  
detect chromosomal aberrations  
as small as 500 bp




# All Classes of Structural Variants Can Be Detected by OGM on the Saphyr System

## Gain/Loss

Deletion




Insertion




## Copy Number Change

Repeat array expansion



Tandem duplication




## Balanced


Translocation



Inversion




## CNV



- Compared to karyotyping, OGM offers much higher resolution in a fully digitized analysis workflow.
- Compared to CMA, OGM closes the gap on balanced rearrangements, including translocations and inversions.

# Circos Plot Allows Visualization of Chromosomal Aberrations

## Bionano Access™ Software



### Visualization Options

- Circos plot
- Genome Browser

### Report

- Export SVs as VCF file and/or PDF report

### Filtering Options

- Size, type of event, confidence score
- Control database (>300 healthy individuals)
- Gene panel or genomic coordinates




# The only software decision support tool for detection of copy number variants from NGS and array data.

- Enables accurate, efficient variant interpretation from a single screen view
- Visualizes multiple tracks of genomic data for at-a-glance context of variant calls
- Releases continuous, community-driven updates that match the pace of innovation in genomics



# OGM Performance



Application	Germline DNA Analysis	Cancer Analysis
<b>Data collected</b>	400 Gbp	1.5 Tbp
<b>Coverage setting</b>	100x	400x
<b>Effective coverage</b>	80x	300x
<b>Variant allele frequency</b>	≥50%	≥5%
<b>Analysis pipeline</b>	<i>De Novo</i> Assembly	Rare Variant Analysis
<b>Resolution by variant type at &gt;90% sensitivity</b>		
<b>Insertions</b>	>500 bp	>5 kbp
<b>Deletions</b>	>700 bp	>7 kbp
<b>Stable Repeat Expansion/Contractions</b>	>500 bp	>5 kbp
<b>Duplications</b>	>30 kbp	>150 kbp
<b>Translocations</b>	>70 kbp	>70 kbp
<b>Inversions</b>	>30 kbp	>70 kbp

Based on Internal Findings. Bionano data on file.


# Bioinformatics Pipeline

## The *De Novo* Pipeline Calls Structural Variants by Comparing Maps to a Reference

- Whole Genome Assembly
- Detects variants 500bp and  $\geq 50\%$  variant allele frequency
- Recommended for constitutional samples


1

Pairwise alignment of all molecules




2

Aligned molecules create a consensus map



3

Comparison to a reference map




# Bioinformatics Pipeline

## The Rare Variant Analysis Pipeline Calls Structural Variants by Comparing Maps to Each Other

- Single molecule tool
- Detects variants 5 kbp and at >5% variant allele fraction
- Recommended for cancer/mosaic samples


1

Single molecule alignment to a reference



2

Molecules with SVs are clustered



3

Local alignment to confirm SV



# Additional Publications



bionano™

# Genetic Disease - Postnatal

bionano™




# Multisite Prospective and Retrospective Study with OGM in Postnatal

## OGM results highly concordant with SOC + OGM led to MORE REPORTABLE VARIANTS

Examples of **NOVEL** findings by OGM:


### UNCLASSIFIED RETROSPECTIVE CASE (DEVELOPMENTAL DELAY, HYDROCEPHALUS, ANOPHTHALMIA)

- Karyotyping results incomplete.
- OGM revealed a more complex rearrangement involving 3 chromosomes, copy number loss, several translocation breakpoints and intrachromosomal foldback junctions.




### RETROSPECTIVE AUTISM SPECTRUM DISORDER CASE, WITH NORMAL SOC. OGM REVEALED:

- A heterozygous 5.5 kbp deletion in *AP1G1*, size and boundary which suggested impact to exons 11-12 or 12-13.
- Subsequent analysis with qPCR confirmed deletion of exons 11 and 12.
- *AP1G1* is related to autosomal dominant Usmani-Riazuddin syndrome




### PROSPECTIVE DEVELOPMENTAL DISORDER CASE. OGM REVEALED:

- Xp22.12 duplications structure with a 69 kbp duplication from chr4 inserted in between the 390 kbp tandemly duplicated segment (chrX:19,547,445-19,937,089).
- The inserted segment from chr4 contains the entire *TLR3* gene and exon 1 of *FAM149A*, and its orientation and position supports a potential fusion with *BCLAF3* on chrX.



Brockel U et al. Multisite Study of Optical Genome Mapping of Retrospective and Prospective Constitutional Disorder Cohorts. medRxiv 2022.12.26.22283900; doi: <https://doi.org/10.1101/2022.12.26.22283900>

# OGM Shows 100% Concordance with SOC in European Consortium Constitutional Cohort Study



n=85 Standard of care method: array-based technology and karyotyping

Tuomo Mantere, et al. "Optical genome mapping enables constitutional chromosomal aberration detection."  
The American Journal of Human Genetics, Volume 108, Issue 8, 2021, pp 1409-1422, ISSN 0002-9297,  
<https://doi.org/10.1016/j.ajhg.2021.05.012>.



# Case Study: OGM Detects a Pathogenic 410bp Duplication & Insertion

## Not Observed with Previous Analysis by Multiple Methods

No findings from first line assessments and advanced Methods...


- Chromosomal Microarray
- PCR and Sanger Sequencing
- Multiplexed Ligation Polymorphism Assay (MLPA)
- Whole Exon & Whole Genome Sequencing



Results from Dr. Eric Vilain – publication pending.

## ...OGM Explained the Molecular Basis of the Disease

Detected a 410kbp duplication & insertion in the DMD gene, resulting in out-of-frame transcription, consistent with Duchenne Muscular Dystrophy\*



# Genetic Disease - Prenatal



bionano™

# Multisite Evaluation and Validation of OGM in Prenatal Cases

In this study OGM provided, in a single assay, results 100% concordant with 2-3 SOC methods combined

200	Datapoints across 123 prenatal samples evaluated, and compared to Standard of Care methods (Karyotyping, FISH, microarray)
100%	OGM results: <ul style="list-style-type: none"><li>• <b>100% concordance</b> with SOC (for samples and variants)</li><li>• <b>100% reproducibility</b> across 9 different sites, different operators and different instruments</li></ul>
75%	75% of the cases originally required 2 or 3 assays to generate the results, while <b>OGM led to same results with a single OGM assay!</b>

Different Sites Involved:



This study demonstrates that while three sequential cytogenetic assays were used to determine genomic structure, OGM accurately predicted the structure in **a single sample-to-answer assay with 100% concordance and 100% reproducibility.**

Stevenson RE et al. Multisite evaluation and validation of Optical Genome Mapping for prenatal genetic testing. medRxiv 2022.12.19.22283552; doi: <https://doi.org/10.1101/2022.12.19.22283552>

# Multisite Evaluation and Validation of OGM in Prenatal Cases


In this study, OGM provided, in a single assay, results 100% concordant with 2-3 SOC methods combined

The ability to **quickly determine** the complexity of genomic aberrations is **critical for prenatal** analysis.

As shown in this example, in multiple cases, OGM resolved **multiple sequential tests in one assay!**

“

OGM has the potential to become a first line assay as it would have likely **reduced the time** to attain comprehensive answers at a **reduced cost**.



Stevenson RE et al. Multisite evaluation and validation of Optical Genome Mapping for prenatal genetic testing. medRxiv 2022.12.19.22283552; doi: <https://doi.org/10.1101/2022.12.19.22283552>

# Large-Scale Study Shows 100% Concordance Between OGM and Cytogenetics in Prenatal Cohort with Additional Findings



AUGUSTA UNIVERSITY  
MEDICAL COLLEGE  
OF GEORGIA

94 amniocentesis samples  
previously characterized by:

- Karyotyping
- FISH
- CMA

100%

## OGM concordance with classical cytogenetics results

Chromosomal aberrations detected include aneuploidies, triploidy, deletions, duplications, translocations, isochromosomes, and LOH

101

## Number of genetic aberrations identified

Resolution of the origin of 3 marker chromosomes and additional unknown material on another chromosome

46%

## Samples with additional actionable findings detected

OGM detected 64 additional clinically reportable SVs in 43 samples



We report the feasibility and relative ease of implementing OGM for prenatal diagnostic testing compared to SOC methods with the platform demonstrating high robust technical and analytical performance and recommend OGM as a first-tier test in prenatal settings.

Kolhe, et al. *medRxiv* (2022 May 16.)  
<https://doi.org/10.1101/2022.05.11.22274975>



# OGM Enables Robust Detection of Cryptic Balanced Chromosomal Rearrangements in Recurrent Pregnancy Loss (RPL)



11 couples investigated for recurrent pregnancy loss (RPL)

Cryptic events successfully identified by OGM

Includes 10 balanced reciprocal translocations and 1 unbalanced translocation



Example of balanced translocation detected by OGM. **Top left:** Karyotype for which this event was cryptic. **Bottom:** map view.

100%

Confirmation with both FISH and sequencing analyses


With further refinement of cryptic karyotypes

100%

Rearrangements identified with highly repetitive sequences

Otherwise difficult to detect with NGS

3



“


With the excellent performance, our research suggests that OGM can be used as a first-line method for detecting cryptic balanced chromosome rearrangements...



Zhang S, Pei Z, Lei C, *et al* Detection of cryptic balanced chromosomal rearrangements using high-resolution optical genome mapping. *Journal of Medical Genetics* Published Online First: 16 June 2022. doi: 10.1136/jmedgenet-2022-108553

# Oncology – Hematological Malignancies

bionano™



# Large Body of Evidence Shows OGM has high-concordance with traditional cytogenetic methods, while unveiling more pathogenic SVs

Reference	Cohort Size	Clinical Referral	Number of Abnormalities Included (Soc)	Concordance with Cytogenetics Results	OGM Additional Findings
<a href="#">Radboud University</a> Neveling et al., 2020	48	AML, MDS, CML, CLL, ALL, MM, MPN, T-PLL, LYBM	112	100%	18 potential gene fusions absent from COSMIC database. 26 insertions/deletions overlapping with well-established cancer genes
<a href="#">Cancer Genomics Consortium</a> Levy et al., 2020	100	AML	NA	100%	3 translocations, 1 inversion, 2 deletions and 1 derivative chromosome
<a href="#">CHU Amiens</a> Lestringant et al., 2021	10	B and T ALL	78	97%	4 fusions, 6 deletions, 2 gains, 1 duplication, 3 complex chromosomal rearrangements
<a href="#">Johns Hopkins University</a> Stinnett et al. 2021	5	Leukemia/Lymphoma and Solid Tumors	30	100%	71 additional calls (7.7% involving cancer genes)
<a href="#">University Hospital Olomouc</a> Kriegova et al. 2021	11	Multiple myeloma	NA	98%	
<a href="#">Augusta, Emory</a> Sahajpal et al. 2022	69	CLL, AML, MDS, MM, lymphoma, PCM, CML, ET and others	164	99%	OGM detected chromosomal aberrations missed by karyotyping and FISH in 35 cases
<a href="#">Hannover</a> Luehmann et al. 2022	12	ALL	NA	~98%	Many new and unknown SVs including gene fusion of JAK2 and NPAT
<a href="#">M.D. Anderson</a> Yang et al., 2022	101	MDS	194	99%	OGM identified 224 cryptic, clinically significant SVs in 34% of pts.
<b>TOTAL</b>	<b>356</b>	<b>VARIOUS</b>	<b>&gt;578</b>	<b>&gt;99%</b>	



# 2022 Comprehensive Study by Augusta University



## OGM outperformed classical methods



59 myeloid and lymphoid neoplasms + 10 controls  
(AML, CLL, MDS, MM, Lymphoma, MPD/MPN, CML)

Compared to Karyotyping, FISH, CMA

- **LOD: 5%** allele fraction for aneuploidy, translocation, interstitial deletion, and duplication
- OGM identified **several additional structural variations**, refined breakpoints, and corrected interpretations

### Performance Metric Evaluation of OGM for Hematological Neoplasms

Performance Criteria	Overall SVs (n=164)
Sensitivity	98.7%
Specificity	100%
PPV/Precision	100%
NPV	98%
Accuracy	99.2%

- Sensitivity/positive percentage agreement = true positive/(true positive + false negative).
- Specificity/negative percentage agreement = true negative/(true negative + false positive).
- PPV = true positive/(true positive + false positive).
- NPV = true negative/(true negative + false negative).
- Accuracy = true positive + true negative/all results.
- NPV, negative predictive value; PPV, positive predictive value; SV, structural variation.



Overall, OGM has outperformed the classical methods in this study and demonstrated its potential as a first-tier cytogenomic assay for hematologic malignancies.

Sahajpal NS, et al. Clinical Validation and Diagnostic Utility of Optical Genome Mapping for Enhanced Cytogenomic Analysis of Hematological Neoplasms. J Mol Diagn. 2022 Oct 17:S1525-1578(22)00290-2. doi: 10.1016/j.jmoldx.2022.09.009.

# Multi-Center Study from Cancer Genomics Consortium



OGM 100% Concordant with classical methods + found additional actionable pathogenic aberrations

100	100 AML cases previously evaluated with one or more classical cytogenetic methods (karyotyping, FISH, CMA)
100%	OGM detected 100% of all key pathogenic SVs and CNVs previously identified by traditional cytogenetic methods, with LOD of 5% allele fraction
13%	Cases had additional pathogenic findings identified by OGM
12%	Cases for which OGM findings would have altered ELN risk-level or identified eligibility for clinical trials



Levy et al.; Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation. *Blood Adv* 2022; bloodadvances.2022007583. doi: <https://doi.org/10.1182/bloodadvances.2022007583>

# Multi-Center Study from Cancer Genomics Consortium



OGM 100% Concordant with classical methods + found additional actionable pathogenic aberrations

OGM findings that could have altered risk-level or led to eligibility to clinical trials

Sample	Significant Cytogenetic Findings From Karyotyping	Significant Cytogenetic Findings From OGM	Change in ELN	Clinical Trial Opportunity
1	t(8;21)	Atypical RUNX1::RUNX1T1 , del(5)		
2	Simple karyotype	CBFB:: MYH11		
3	Normal karyotype	ETV6::MECOM		
4	Simple karyotype	7q deletion, RUNX1 deletion		
5	Normal karyotype	NUP98::NSD1		
6	Normal karyotype	NUP98::NSD1		
7	Simple karyotype	KMT2A::MLLT3		
8	del(17p)	Complex		
9	Mono 17, monosomal karyotype	Complex		
10	del(5q), del(17p)	del(5q)		
11	del(5q), del(17p)	del(5q), del(17p), KMT2A r		
12	del(5q), mono 7, del(17p)	del(5q), mono 7		

“ The results from this multi-institutional study indicate that OGM effectively recovers relevant SVs and CNVs found by standard of care methods and reveals additional SVs not reported.


Furthermore, OGM minimizes the need for labor-intensive multiple cytogenetic assays while concomitantly maximizing detection through a standardized workflow.

Levy et al.; Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation. *Blood Adv* 2022; bloodadvances.2022007583. doi: <https://doi.org/10.1182/bloodadvances.2022007583>

# Oncology – Solid Tumors

bionano™

---




# OGM as a tool for Homologous Recombination Deficiency (HRD)

OGM provides high sensitivity and specificity for SV detection and HRD stratification.  
More cost effective, and simpler to analyze, as compared to WGS, even in samples with low tumor content

## PART II OF THE STUDY:

Comparison between whole-genome sequencing and OGM in an HRD triple negative breast carcinoma (TNBC) sample



100%

Concordance between WGS and OGM, for all structural variant events  $\geq 5\text{kb}$  in size

17

Additional Structural Variants found with OGM only



Our results demonstrate that the OGM technology is an **affordable way of getting an insight of the structural variants present in solid tumors, even with low tumoral cellularity.**

**It represents an alternative technology for HRD analysis, which should now be evaluated in independent series of tumors of different tissue origins.**

Vanhuele et al. Optical Genome Mapping for detecting Homologous Recombination Deficiency (HRD) in human breast cancers. bioRxiv 2022.12.23.521790; doi: <https://doi.org/10.1101/2022.12.23.521790>

# OGM as a tool for Homologous Recombination Deficiency (HRD)

OGM provides high sensitivity and specificity for SV detection and HRD stratification.

More cost effective, and simpler to analyze, as compared to WGS, even in samples with low tumor content

## PART II OF THE STUDY:

Expanded analysis of OGM performance, for HRD characterization, in a cohort of **15 triple negative breast carcinoma (TNBC) samples:**


- 8 samples were HRD (Homologous Recombination Deficient)
- 7 samples were HRP (Homologous Recombination Proficient)

Samples from RadioPARP clinical trial.

RD status was previously detected by low coverage WGS approach




OGM allowed clear stratification of HRD and HRP samples



OGM Circos Plots for 4 representative examples of triple-negative breast carcinomas (TNBC) samples

HRD CASES


HRP CASES



OGM Results:

high correlation to low coverage WGS.


(The only outlier sample was a sample with low tumor content, which may explain why shallow WGS underestimated the amount of large-scale genomic alterations as compared to OGM.)



Vanhuele et al. Optical Genome Mapping for detecting Homologous Recombination Deficiency (HRD) in human breast cancers. bioRxiv 2022.12.23.521790; doi: <https://doi.org/10.1101/2022.12.23.521790>

# Optical Genome Mapping is Powerful for Detecting Pathogenic Structural Variants (SVs) in Solid Tumors

Several SVs map to known cancer genes, and many would not be readily identified by NGS gene panels



Goldrich, D.Y.; LaBarge, B.; Chartrand, S.; Zhang, L.; Sadowski, H.B.; Zhang, Y.; Pham, K.; Way, H.; Liu, C.-Y.J.; Pang, A.W.C.; Clifford, B.; Hastie, A.R.; Oldakowski, M.; Goldenberg, D.; Brach, J.R. Identification of Somatic Structural Variants in Solid Tumors by Optical Genome Mapping. *J. Pers. Med.* 2021, 11, 142. <https://doi.org/10.3390/jpm11020142>  
For Research Use Only. Not for use in diagnostic procedures.

# Combining OGM + WGS led to resolution of complex rearrangements in Hepatocellular Carcinoma


- OGM and WGS were combined to explore SVs induced by replication stress in cyclin-activated hepatocellular carcinomas
- WGS alone could not resolve complex events involving several distant regions interconnected by abnormal intra/inter-chromosomal junctions



“ By combining WGS and optical mapping, we could reconstruct the structure of complex SVs both at large scale and single-base resolution in a subgroup of HCC with cyclin-induced replication stress.

1.4x  
MORE

SVs were detected by OGM, as compared to WGS alone, ranging from classical tandem duplications to complex tumor initiating cells (TICs) with multiple template-switching events



Bayard Q, et al. Impact of Replication Stress–Induced Structural Variants in Hepatocellular Carcinoma. *Cancer Res* 15 April 2022; 82 (8): 1470–1481. <https://doi.org/10.1158/0008-5472.CAN-21-3665>



# OGM identifies causative variant, solving cancer predisposition mystery in pediatric ATRT cancer



Sanger seq, MLPA, WES and WGS previously used with no driver alteration identified



When OGM was applied, it identified a 2.7kb insertion previously missed, falling into *SMARCB1* gene, a known driver of ATRT

ATRT: Atypical teratoid rhabdoid tumor

Sabatella M, et al. Optical genome mapping identifies a germline retrotransposon insertion in *SMARCB1* in two siblings with atypical teratoid rhabdoid tumors. *J Pathol.* 2021 Oct;255(2):202-211. doi: 10.1002/path.5755.




The high GC and repeat content explained why the variant was difficult to detect by NGS and incriminated a retrotransposon that disrupted the *SMARCB1* gene.



Radboud umc  
university medical center



Princess maxima center  
pediatric oncology



# Testimonials

bionano™



OGM reveals more CNVs  
and SVs, allowing Dr. Dubuc  
and his team to further their  
understanding of B-ALL.

*Dr. Adrian Dubuc  
Harvard Medical School Brigham and Women's Hospital  
Massachusetts, USA*



“OGM allows next generation cytogenetics and enables the identification of hidden structural variants as a cause of rare diseases.”

*Alexander Hoischen, PhD  
Radboud UMC  
The Netherlands*



# OGM enables Dr. Lühmann to find novel aberrations in ALL.

*Jonathan Luhmann, PhD Student  
Department of Human Genetics  
Hannover Medical School*



“OGM revealed important translocations, in Ewing sarcoma samples, that could be useful as a prognostic marker for patients with poor clinical outcome.”

*Dr. Juan Diaz Martin  
Instituto de Biomedicina de Sevilla (IBiS)  
Sevilla, Spain*



“Balanced translocations,  
primarily detected by  
karyotyping for the last 50  
years, are solved by OGM.”

*Dr. Gopalrao Velagaleti, PhD  
UT Health San Antonio  
Texas, USA*



“The results of the study demonstrate that we are grossly under-evaluating the degree of genomic aberrations.”

*Dr. Rashmi Kanagal-Shamanna  
MD Anderson Cancer Center  
Texas, USA*





“OGM reveals more of what matters: more clinically relevant SVs leading to higher success rates and resolution of unsolved cases.”

Dr. Laïla El-Khattabi  
Hôpitaux de Paris  
*(AP-HP)-Université de Paris*

